Navigation Links
Abbott Announces Earnings Guidance for 2009
Date:1/12/2009

ABBOTT PARK, Ill., Jan. 12 /PRNewswire-FirstCall/ -- Abbott today is announcing its full-year earnings-per-share guidance for 2009 and confirming its previously issued 2008 earnings-per-share guidance of $3.31 to $3.33, excluding specified items. For 2009, the company expects earnings per share of $3.65 to $3.70 under Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. The midpoint of this 2009 guidance reflects double-digit growth over the midpoint of 2008 earnings-per-share guidance.

Abbott's 2009 outlook includes the acquisition of Advanced Medical Optics (AMO) as announced today (see separate news release). Abbott expects the AMO transaction to be neutral to ongoing earnings per share in 2009 and accretive in 2010, both before one-time transaction-related costs, which will be provided at a later date.

Further details regarding Abbott's earnings-per-share guidance for 2009 will be provided on the company's fourth-quarter 2008 earnings conference call scheduled for Jan. 21, 2009. Including net specified items, Abbott forecasts earnings per share for the full-year 2008 under GAAP of $3.04 to $3.06. Abbott forecasts net specified items for the full-year 2008 of $0.27 per share, primarily associated with previously announced cost reduction initiatives, acquired in-process R&D, and litigation settlements. These items were partially offset primarily by previously announced one-time gains from the sale of Abbott's spine business, conclusion of the TAP joint venture, and favorable tax settlements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 co
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
2. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
3. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
4. Abbott Hosts Conference Call for Third-Quarter Earnings
5. Abbott to Present at UBS Best of Americas Investment Conference
6. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
7. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
8. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
11. Abbott to Present at Goldman Sachs Global Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...obal temperatures and energy costs continue to soa...stainable future. An attractive replacement for ...online in Genome Research ( www.genome.org ), sc...oethanol-producing microorganisms, uncovering gene...technologies needed to implement production on a g...
(Date:11/6/2009)...v. 6 Helix BioPharma Cor...nounced that John Docherty, president and chief op...ord,s 6th annual Investor Summit on November 10, 2...ty. Mr. Docherty will provide an overview of the ...OS47 and Topical Interferon Alpha-2b. The slide s...
(Date:11/6/2009)...Newswire-FirstCall/ - Oncolytics Biotech Inc. (TSX... today announced updated results from a Phase II s...arcomas metastatic to the lung in a poster present...y Society Meeting held in Miami Beach, Florida, fr...ntitled "A Phase II Study of Intravenous REOLYSIN ...
(Date:11/5/2009)...Nov. 5 The endangered black-footed...U.S. This rare carnivore feeds on prairie dogs. ...nd often entire population die-offs in towns occur...implemented a ferret breeding program and has been...merly native habitat. Unfortunately, plague can s...
Breaking Biology Technology:Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
...rgies to Raising Awareness and Funds to, Advance ... Neurological, Other Serious Me...The Focused Ultrasound,Surgery Foundation, founded...n of a breakthrough therapeutic technology -- Magn...- is pleased to announce that author,John Grisham ...
...August 13, 2008 at 9:00 a.m. ET --, BEIJING, Aug....mex:,SVA), a leading developer and provider of vac...ncial results for the six and three-month,periods ... -- Sales increased 73% year-over-year to $16.5 mi...p 55%, and 180,000 doses of Bilive(R) based on...
...t 2:00 p.m. CET, AMSTERDAM, August 13 Amsterdam ...n the field of human gene therapy,today reported i...hlights, - Positive results of pivotal trial for ...e I - European patent for treatment of Non-Alcoho...of Duchenne Muscular Dystrophy from La Sapienza U...
Other Biology Technology:John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technology's Potential to Help 'Millions of Patients' 2John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technology's Potential to Help 'Millions of Patients' 3Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 2Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 3Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 4Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 5Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 6Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 7Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 8Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 9Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 10Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results 11Amsterdam Molecular Therapeutics Reports Half Year Results 2008 2Amsterdam Molecular Therapeutics Reports Half Year Results 2008 3Amsterdam Molecular Therapeutics Reports Half Year Results 2008 4
(Date:11/4/2009)...2009 Childhood obesity in the United States is re...urth of advertising on daytime and prime time tele...ng questions about the role television plays in ob...he Journal of Nutrition Education and Behavior e...ht be a large contributor to the problem. , Rese...
(Date:11/4/2009)...at deciphered the DNA codes, or genomes, of the fa...oined The Genome 10K Project, an international eff...nces on 10,000 species of animals for conducting c...ot be achieved. , Participating in The Genome 10...ov. 5, 2009 issue of the Journal of Heredity , ar...
(Date:11/4/2009)... Oct. 19 Spectros, developer and m...ing devices which shed light on life-threatening d...ive distribution deals for both its T-Stat® V...ed include Australia, New Zealand, The Netherland... France, Spain, Portugal, Poland, Greece, Turkey, ...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Mayo Clinic researchers lead national trial testing new treatment for chronic severe indigestion 57531 1Mayo Clinic researchers lead national trial testing new treatment for chronic severe indigestion 57531 2Mayo Clinic researchers lead national trial testing new treatment for chronic severe indigestion 57531 3Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 1Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 1National new biology initiative offers potential for remarkable and far reaching benefits 9968 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 3
...ble in Spanish . , The research reveals that a...comes accustomed to the presence of an exogenous s...dependence on an external source--in this case, al...p "Alcoholism and drug addiction" , of the Unive...reasons to become alcoholic, many social, family, ...
...s to change from carnivorous insect eaters to plan...ocial insects rapidly spread throughout coastal Ca...y native insects and creating ant infestations fam...the University of California, San Diego and the Un...rtunistic, changing dietary preferences of Califor...
...emain through reporting of 2007 fiscal year, BEDF... leading supplier of broadband technology and biom...g will resume the position of Chief,Financial Offi...viously,Aware,s CFO from June 1996 until September...e departing in February after,Aware has completed ...
Other Biology News:A research of the UGR shows the genetic predisposition to develop alcohol abuse 2Study links success of invasive Argentine ants to diet shifts 2Study links success of invasive Argentine ants to diet shifts 3Aware, Inc. Announces Richard Moberg to Return as CFO 2Aware, Inc. Announces Richard Moberg to Return as CFO 3
Mycoplasma Testing from AbD Serotec
...Exonuclease-free Klenow Fragment is a genetically ...xonuclease activity has been removed, leaving only...f exonuclease activity makes Exo- Klenow Fragment ...ng of DNA probes by the random primed method, and ...
T4 RNA Ligase from Roche Applied Science
T7 RNA Polymerase from Roche Applied Science
Biology Products: